Ann: Imugene Appoints Kim Drapkin as Non-Executive Director, page-79

Or does the company know more than we do, and it's exactly what we need. Perhaps they believe we will be a midcap in the near future once certain science makes its way into certain journals and by extension the media.

I personally don't think this is about capital raising. We have more than enough capital for the meantime and given the caliber of the news we are anticipating for CF33 to generate if it's able to replicate in humans what it's done in mice, we very much need to stack the board with those experienced beyond our current size.

Just my thoughts, obviously differ to others. Either may be right at the end of the day.

I think the science will do the talking and capital raisings are not something that would be the basis for this strategic move.